Aptose delays closing of Hanmi arrangement; targets May 2026 for completion

Aptose Biosciences Inc.

Closing delayed as Korean regulatory approvals remain in progress; parties do not anticipate prevention.
Hanmi will acquire all outstanding Aptose shares at C$2.41 per share, a 28% premium to C$1.88 VWAP.
Transaction originally announced Nov 19, 2025; closing expected in May 2026.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.